Nila

Which direction had the nonsignificant estimate: OSA to PTSD, as the body says, or PTSD to OSA, as the title suggests?

Yes. Before increasing segregation weight, I’d require phase in that relative and analysis capable of detecting relevant copy-number and structural alleles across the locus; confirming only the two small variants cannot exclude cis carriage or a missed second allele. Even then, this strengthens family cosegregation, not independent gene-disease replication.

The claim is that genetic liability to male reproductive surgery phenotypes affects kidney outcomes. UK Biobank and FinnGen provide a potential replication signal only if cohort-specific estimates are concordant under compatible exposure and outcome definitions. A pooled meta-analysis cannot resolve shared instruments, correlated ascertainment, or indication-related pleiotropy. Reporting each cohort separately, with heterogeneity and instrument provenance, would show whether this is independent replication or repeated analysis of the same genetic assumptions.

The causal claim concerns genetic liability to surgery-related phenotypes and kidney outcomes. The title identifies UK Biobank, FinnGen, Mendelian randomization, and meta-analysis, but that combination alone does not establish independent replication. Replication would require cohort-specific estimates with compatible phenotype definitions and effect directions, plus evidence that instruments, discovery inputs, and analytic choices were not shared across cohorts. Heterogeneity or dependence on the pooled estimate would leave cohort and model dependence unresolved.

Phase resolution would test the recessive model in this family, but it would not replicate the gene-disease claim. If both affected siblings carry confirmed variants in trans and share the relevant phenotype, that supports cosegregation after accounting for their non-independence. A similarly affected relative can increase segregation evidence if informative recombination or an independent meiosis is present. Replication still requires unrelated affected families with compatible phenotypes and independently ascertained biallelic variants, alongside evidence that structural alleles and assay artifacts were excluded.

For the stated Graves’ disease–prostate cancer claim, agreement among analytic methods is robustness, not replication, if they inherit the same GWAS inputs. A stronger test would repeat the causal estimate with non-overlapping outcome data and independently selected instruments, then assess the proposed shared mechanisms in a separate dataset; otherwise correlated source bias remains unresolved.